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Ways of Understanding and Measuring Metacognition in Schizophrenia Spectrum 
Disorders: A Systematic Review 
 
Abstract 
Metacognition is described as the awareness and understanding of mental states 
underpinning social behaviours. There is increasing interest in the role of metacognition 
in understanding symptoms and recovery in Schizophrenia Spectrum Disorders (SSD). But, 
to progress this research the various ways of conceptualising and measuring 
metacognition warrant systematic review and integration. For instance, because lab-
based tests of discrete metacognitive processes have poorer ecological validity there has 
been a growth in research focused on measuring more complex aspects of metacognition. 
This diversification of measurement tools and concepts makes it timely to provide an 
integrative review. This review aimed to identify the various methods of assessing 
metacognition and evaluated the relative strengths and weaknesses of each method. 
Three databases were searched, a key journal was hand searched and an academic with 
knowledge of the literature was consulted, resulting in 19 papers for review. Five 
measures were included and rated for quality. Quality ratings ranged from low to 
moderate scores with low ratings typically due to failure to include participants in the 
generation of scales, insufficient evidence for factor structure, failure to examine 
floor/ceiling effects and limited interpretability. This review provides a summary of the 
relative strengths and weaknesses of the measures that can be used to guide 
measurement choices in future research. 
 
Keywords  
Metacognition, Theory of Mind, Psychosis, Schizophrenia Spectrum Disorders, 
Assessment 
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Introduction 
Defining Metacognition 
The term metacognition was first used in the context of education to denote the ability to 
think about the thinking process while learning (Flavell, 1979). It has since come to define 
a much broader and more varied range of cognitive abilities and actions in the realm of 
social cognition. The associated concept of mentalisation has been used to describe an 
awareness and understanding of mental states, in oneself and others. This capacity is 
thought to underpin many human social behaviours.  
 
It has been proposed that mentalisation is the mechanism that allows humans to 
understand the social world and their place within it (Fonagy, 1991; Bateman & Fonagy, 
2010, Fonagy et al.,2002). Integrating psychoanalytic, developmental and neurocognitive 
thinking, Fonagy developed a theory of mentalisation as a developmentally achieved 
capacity. Mentalisation is related to metacognition but is conceptualised differently in 
that disturbed metacognition is not thought to occur only in the context of disturbed 
attachment (DiMaggio & Lysaker, 2015). Paul Lysaker and colleagues define 
metacognition as ‘a spectrum of activities’ that range from the experience of discrete 
cognitions through to the integration and synthesis of these into complex representations 
of the self and of others. These complex representations are understood to interact and 
influence one another and this synthetic ability allows people to form ideas about 
themselves and others in ‘the flow of daily life’ (Lysaker, DiMaggio and Brüne, 2014, 
p.100). Discrete acts of metacognition such as those often assessed by Theory of Mind 
(ToM) tasks (hinting, reading emotion in the eyes, irony detection, prosody 
understanding, visual jokes) differ from the integrative operations required to reflect on 
the mind of the self and other and to use that knowledge to adapt to the challenges of 
life. 
 
There are also other ways of conceptualising metacognition. In the information 
processing model of metacognition advanced by Wells and Matthews (1994), 
disturbances of metacognition are formulated as central to the development of 
psychological difficulties. In the Self-Regulatory Executive Function (S-REF) model, 
vulnerability to psychological dysfunction and maintenance of impairments are 
associated with a cognitive-attentional ‘syndrome’ characterised by heightened self-
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focused attention, threat monitoring, cognitive rumination, activation of dysfunctional 
beliefs, and self-regulation strategies that fail to modify maladaptive self-knowledge. 
These processes are driven by the individual’s metacognitive beliefs that predispose them 
to the use of ruminative cognitive processing, maintain congruent selective attention and 
facilitate the interpretation of cognitive events. The model predicts an involvement of 
metacognitive beliefs in vulnerability to and the maintenance of psychopathology. 
 
Another concept closely linked with metacognition is social cognition. This refers to 
processes involved in thinking about social interactions such as theory of mind, emotion 
processing and attributional style and is concerned with the accuracy of social 
perceptions and representations (Pinkham et. al., 2014). Social cognition is the ability to 
form complex ideas about social exchanges but it differs from metacognition because it is 
more concerned with the cognitive process driving social acts, whereas metacognition 
refers primarily to reflexive qualities, that is awareness of and ability to reflect on mental 
states of the self and others. There are overlaps between social cognition and 
metacognition in discrete mental activities including ToM and affect recognition (Lysaker, 
et. al., 2010). 
 
The conceptual breadth of use within the literature creates challenges for researchers 
(Buck, Minor & Lysaker, 2015). Even a brief review of the literature demonstrates that 
terms such as ‘mentalisation’, ‘metacognition’ and ‘theory of mind’ are used virtually 
interchangeably (Lysaker, DiMaggio, et. al., 2007) and that these terms are used to refer 
to various cognitive operations which range in complexity, clinical relevance and 
applicability. Lysaker and colleagues (2007) argue that metacognition encompasses a 
range of concepts, which are semi-independent and overlap with other faculties, such as 
insight, empathy and imagination. Therefore, a structured review of the 
conceptualisation and measurement of metacognition is timely.  
 
Metacognition in Schizophrenia Spectrum Disorders 
Lab-based assessment of metacognition lack ecological validity and although the 
outcomes of the tasks provide information about deficits, they do not provide 
information about what helps or what might be remediated through cognitive therapies. 
As a result, methods of evaluating synthetic metacognitive processes had to be 
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developed. These generally make use of semi-structured interviews and the analysis of 
transcripts according to standardised methods which can be evaluated for inter-rater and 
repeated-rater validity. Metacognitive functioning has been evaluated in people with SSD 
compared to metacognition in people with addictions (Lysaker et. al., 2014; Vohs et. al., 
2014), bipolar disorder (Tas et. al., 2014), anxiety (Wells & Carter, 2001), PTSD (Lysaker 
et. al., 2015), prolonged medical conditions (Lysaker et. al., 2014) and healthy controls 
(Hasson-Ohayon, et. al., 2015). The severity of metacognitive deficits has also been linked 
to concurrent levels of negative symptoms (Nicolò et. al., 2012; Rabin et. al., 2014) and 
with longer duration and severity of negative symptoms (Hamm et. al., 2012). More 
generally, given that metacognition is fundamental to forming a cohesive idea of the self 
and others, impairments in this faculty will negatively impact on the ability to make sense 
of one’s life and those in it (DiMaggio & Lysaker, 2015). 
 
Varese, Barkus and Bentall (2012) found limited support for a causal role of 
metacognition in hallucinatory experiences; when controlling for comorbid symptoms, 
associations between metacognitive beliefs and hallucinations were reduced. This 
suggests that metacognitive beliefs may have a more general role related to symptom 
maintenance, help-seeking, and distress (Sellers, et. al., 2016). Consistent with this, 
subsequent studies have shown that elevated metacognitive beliefs are associated with 
increased distress (Barbato et al., 2013; van Oosterhout et al., 2013) and a more severe 
and chronic course of illness (Austin et al., 2015). 
 
Deficits in synthetic metacognition might create a substantial barrier for people 
diagnosed with SSD in reflecting on their learning from life experiences, applying this 
knowledge to negotiate complex social tasks. Impairments in metacognition have been 
found to be present prior to the diagnosis of SSD and so may reflect cognitive traits 
(Moritz & Woodward, 2007) that can mediate the relationship between 
neuropsychological deficits and functional outcome. This has recently been demonstrated 
in a sample of individuals presenting with a first episode of psychosis (Davies, Fowler & 
Greenwood, 2017). Moritz and Woodward (2007) identified metacognitive training as an 
effective method of intervention which aims to inform people diagnosed with SSD about 
cognitive biases and to provide corrective experiences to patients with the hope that it 
will improve symptoms and reduce the risk of relapse.  
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Measuring Metacognition in SSD 
Early conceptualisations of metacognition focussed on discrete acts that demonstrated 
ToM; that is, the awareness of one’s own mind and the mind of the other in terms of 
emotional states and anticipated behaviour. Bell et al. (2010) differentiate between 
discrete social-cognitive ToM tasks, such as understanding irony and metaphor or 
appreciating visual jokes, ‘social-perceptual ToM tasks’, such as inferring mental states 
from eye expressions and more complex assessments based on structured interview. In 
research that concerns the real-world experience of individuals, these former tests have 
limited power to answer questions about how cognition and perception affects 
understanding of and action within the world. The latter assessments based on interview 
and discourse analysis are likely to be more directly helpful in developing interventions 
that address impairments in metacognition. 
 
Measuring ToM is relatively simple and can provide reliable measures of deviation from 
normal task performance. Assessing a wider range of metacognitive abilities helps with 
understanding possible correlates of recovery, by exposing the treatment approaches 
that allow remediation of synthetic metacognition. Given that synthetic metacognition is 
more relevant to real-world contexts and clinical practice, this will be the area of interest 
to this review. This paper seeks to answer questions pertaining to the theoretical 
underpinnings and psychometric properties of synthetic metacognition assessment 
methods. 
 
Complex Metacognition: a definition 
In this paper, synthetic metacognition is defined as semi-independent faculties that 
facilitate the ability to think about and integrate discrete metacognitive components on 
three dimensions: (1) awareness of and knowledge about one’s own mind; (2) awareness 
of and knowledge about other’s minds and (3) the ability to integrate and apply this 
knowledge to respond and adapt to interpersonal experiences and life’s challenges. 
 
Objectives 
This review aims to describe both how complex metacognition is measured in research 
with people diagnosed with SSD and the psychometric properties of the methods used. 
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Method 
The review was conducted in three phases. The first phase involved a search for and 
screening of relevant literature. The second phase involved exploring this literature to 
identify measures of synthetic metacognition. The reference sections of these papers 
were reviewed to identify papers which described the development and validation of the 
measures.  The third phase focused on reviewing the quality of the measures using pre-
defined criteria derived and adapted from Strauss and colleagues (2016). 
 
Phase 1: Study Identification 
Establishing Search String and Conducting a Computerised Database Search 
In collaboration with an expert librarian, a search algorithm was developed which would 
enable a systematic search of published literature. A comprehensive list of key words was 
compiled, based on relevant literature. There were three main components to the search 
string: metacognition, SSD and assessment. The search string was piloted and adjusted 
until sufficient scope was attained.  
 
Truncation ($) was used to maximise search sensitivity. Key words within each 
component were combined using the Boolean operator ‘OR’ and the four components 
were combined using ‘AND’.  
 
Final Search String 
 Metacogniti$ OR reflexiv$ OR (reflective function$) OR mentali$ OR (theory of 
mind) 
 Psycho$ OR psychotic OR schizo$ OR (schizophrenia spectrum disorder) 
 Measur$ OR analy$ OR scale$ OR assess$ 
 
The following limits were applied to focus the output of the search:  
 Language: English language papers.  
 Type of citation: abstract available.  
 
The search was conducted using three databases: Ovid Medline, PsycINFO (hosted by 
Ovid) and the Psychology and Behavioural Sciences Collection (hosted by EBSCOhost). To 
test the sensitivity of the search string, the reference section of each paper identified was 
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searched for further potentially relevant papers. An expert in the field was consulted to 
ensure that no key papers had been overlooked. A key journal, Schizophrenia Research, 
was hand searched.  
 
Screening for Relevance and Inclusion  
Articles were subjected to the following screening process: abstracts were reviewed for 
inclusion criteria, proceeding to scrutiny of the methods section where sufficient 
information could not be obtained.  
 
Inclusion Criteria:  
 Study must have reported data pertaining to participants with diagnosis of SSD 
 Must directly measure or quantify synthetic metacognition 
 Papers that report psychometric properties of the metacognition assessment tool 
 Adult sample (aged 18 and over) 
 English language papers 
 Must present primary data  
 
Exclusion Criteria:  
 Papers reporting only discrete dimensions of metacognition 
 Case studies 
 Unpublished studies 
 Reviews, meta-analysis, conference abstracts, book chapters, unpublished 
dissertations. 
 
The principal reviewer carried out the screening process, consulting with a research 
advisor in cases where there was any doubt about an article meeting inclusion criteria. All 
articles that did not meet inclusion criteria were discarded. Where inclusion criteria were 
met, the paper progressed to the next stage of review. 
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Figure .1: PRISMA flow diagram of search strategy 
 
Phase 2  
Identification of Measures  
The nineteen papers identified by Phase 1 were read used to identify measures which had 
been applied in the measurement of synthetic metacognition. Using the reference 
sections of these papers it was possible to identify papers providing information about 
the development and validation of these measures. These were reviewed and their 
reference sections were consulted to scope for further relevant papers detailing concept 
development or psychometric assessment.   
 
Phase 3 
Analysis of Quality  
Analysis of the quality of papers was adapted from the method used by Strauss and 
colleagues (2016) in a systematic review of the definition and measurement of 
compassion. Measures were rated using Terwee and colleagues (2007) quality criteria for 
Database search 
1863 
Title & abstract review 
951 
Papers for full text review 
69 
912 duplicates excluded 
882 excluded upon application of 
inclusion/exclusion criteria 
50 excluded upon full text review: 
 11 did not measure concept of 
interest 
 39 did not report psychometric 
properties of measure 
Papers for analysis 
19 
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health status measures and Barker, Pistrang and Elliott’s (2002) ‘rules of thumb’ for 
evaluating psychological measures. Terwee and colleagues measure awards a positive, 
intermediate or negative rating, or a rating of 0 where no information regarding the 
criterion is provided. Following the method of Strauss and colleagues, to make scores 
easier to interpret, in this review measures were given a score of 2 if there was evidence 
of the criterion being fully met, 1 or 0.5 if there was partial attainment (depending on the 
number of components being assessed within the factor), and 0 if the criterion was not 
met or the information was not reported. Scores were aggregated to provide an overall 
rating. A second researcher scored a sample of the measures and any discrepancies were 
resolved by discussion. Measures were rated across the following domains: 
1. Content validity: the extent to which the domain of interest was sampled by the 
measure. The domain of interest was metacognition as defined in this review, 
rather than as defined by the scale authors.  
2. Factor structure: whether the factor structure for the measure has been examined 
and supported.  
3. Internal consistency: the extent to which items in a scale or subscale are inter-
correlated and this measuring the same construct.  
4. Test-retest reliability. 
5. Convergent and discriminant validity: the extent to which scores on a scale relate 
to other measures in a manner consistent with theoretically derived hypotheses. 
validity, thus this is required for a score of 2 to be awarded. 
6. Floor and ceiling effects: the number of respondents achieving the highest or 
lowest possible scores.  
7. Interpretability: how differences in scores on the measure can be interpreted, or 
the degree to which qualitative meaning can be attached to quantitative scores.  
8. Inter-rater reliability: the reliability of observations across raters on observational 
as opposed to self-report measures.  
See Appendix 1.3 for detailed description and scoring anchors. 
 
Results  
The process by which papers were selected for inclusion is illustrated in Figure 1. The 
search of electronic databases yielded a combined number of 1863 papers. These were 
transferred into Mendeley reference management software. 912 duplicate papers were 
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identified and removed from the sample. The remaining 951 papers were reviewed by 
title and abstract for relevance using the pre-defined criteria. Where there was dubiety, 
the method section of the full text article was reviewed. A further 882 papers were 
excluded based on inclusion and exclusion criteria and 69 papers progressed to the next 
phase of review. A further 50 papers were excluded at full text review, resulting in a final 
sample of 19 papers from the database search.  
 
Table 1: Summary of quality ratings 
Measure Quality Criterion 
 
MAS-A 
 1 2 3 4 5 6 7 8 Total 
Abu-Akel et al 2015 1.5 0 0 0 1 0 0 2 4.5 
Hamm et al  2012 1.5 0 0 1 1 0 1 2 6.5 
Hasson-Ohayon et al  2015 1.5 0 1 0 2 0 1 1 6.5 
Lysaker et al  2005 1.5 0 0 0 2 0 0 2 5.5 
Lysaker, Buck et al 2008 1.5 0 1 0 1 0 1 2 6.5 
Lysaker, DiMaggio et al 2007 1.5 0 1 0 0 0 2 2 6.5 
Lysaker, Ringer et al 2012 1.5 0 1 0 1 0 1 0 4.5 
Lysaker, Vohs et al  2014 1.5 0 1 2 1 0 1 1 7.5 
Lysaker, Warman et al 2008 1.5 0 0 0 1 0 0 1 3.5 
Lysaker, DiMaggio et al 2010 1.5 0 0 0 1 0 1 2 5.5 
Tas, Brown et al 2014 1.5 0 1 2 0 0 1 0 5.5 
Trauelson et al 2016 1.5 0 1 0 1 0 2 0 5.5 
Vohs, Lysaker et al 2014 1.5 0 0 0 0 0 1 1 3.5 
Vohs, Lysaker et al 2015 1.5 0 0 0 1 0 0 1 3.5 
MCQ-30 
  1 2 3 4 5 6 7 8 Total 
Austin et al  2015 1.5 2 1 1 0 0 1 0 6.5 
Van Oosterhout et al  2013 0.5 0 1 0 0 2 0 0 3.5 
Østefjells et al 2015 1.5 0 1 0 0 0 0 0 2.5 
Sellers et al 2016 1.5 0 2 0 2 0 1 0 6.5 
Valiente et al  2012 1.5 0 2 2 0 0 0 0 5.5 
 
Description of Measures 
Metacognition Assessment Scale (MAS) 
Metacognitive Assessment Scale (Semerari et. al., 2003) was developed based upon three 
hypotheses: that metacognitive function has a modular structure; that for each type of 
psychopathological condition there is a different metacognitive deficit profile and that to 
be successful psychotherapy needs to involve an improvement in any deficient 
metacognitive sub-function. 
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The MAS was initially proposed and provisionally validated in a very small sample (n=2) of 
individuals diagnosed with personality disorder therefore it was not identified in the 
electronic search carried out pertaining to the question of interest to this review. 
However, given that the interview-based measure that has been widely used in research 
concerning SSD, it was pertinent to include information summarising the development 
and validation of the MAS and the quality rating assessment is presented in Table 2. 
 
In terms of convergent validity and interpretability of results, the authors acknowledge 
that the presentation of data from two individuals does not allow for inferences to be 
made about the properties of the tool. Rather they are presenting data regarding the face 
validity and acceptability of the MAS to patients and practitioners in the very early stages 
of development. The total score on the quality rating is 4 out of 16. The MAS was then 
adapted, abbreviated and validated as detailed overleaf. 
 
Metacognitive Assessment Scale – Abbreviated (MAS-A) 
Metacognition Assessment Scale - Abbreviated (MAS-A; Lysaker et. al., 2005) is a rating 
scale that assesses synthetic metacognitive capacities. Lysaker and colleagues (2005) 
adapted this scale in collaboration with the authors of the original MAS (Semerari et. al., 
2003).  
 
Information pertaining to the qualitative interpretability of the quantitative scores was 
not reported in this paper, scoring 0 on the quality rating. Correlations between scores on 
the MAS-A and measures of neurocognition, quality of life (QoL) and symptoms were 
identified (r>.50), giving a score of 2 for convergent and discriminant validity. A total 
score of 5.5 out of 16 was attained on application of the quality criteria. Details of 
psychometric properties are presented in Table 3. 
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Table 2: Psychometric properties of the MAS (Semerari et. al., 2003) 
Sample N Content validity: 
factors 
Content 
validity: 
Items 
Proposed 
factor structure 
Support for 
factor structure 
Internal 
consistency: sample 
size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Inter-rater 
reliability: W 
Personality 
disorder 
2 3 (1) Experts = yes 
Recipients = 
no (1) 
Not reported Not reported 
(0) 
Not reported (0) Not reported (0) Not reported 
(0) 
0.935 0.931 
p<.01 (2) 
 
Table 3: Psychometric properties of the MAS-A (Lysaker et. al., 2005) 
Sample N Content 
validity: factors 
Content 
validity: 
Items 
Proposed factor 
structure 
Support for factor 
structure 
Internal consistency: 
sample size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Inter-rater 
reliability: r,  
SSD 61 3 (1) Experts = yes 
Recipients = 
no (.5) 
3 factor structure Not reported (0) N<100 (0) .39-.59 (0) Not reported 
(0) 
.89 (2) 
 
Table 4: Psychometric properties of MAI (Semerari et. al., 2012) 
Sample N Content 
validity: 
factors 
Content 
validity: 
Items 
Proposed 
factor structure 
Support for factor 
structure 
Internal 
consistency: sample 
size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Inter-rater 
reliability: r,  
Non-
clinical 
175 3 (1) Experts = yes 
Recipients = 
no (1) 
4 factor 
structure 
EFA, 2 factor model, CFA – 
partial confirmation (1) 
N>100 = Yes (1) .85-.91 = Yes (1) Not reported 
(0) 
.41-.76 
p<.0001 (1) 
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Metacognitive Assessment Interview (MAI) 
The MAI is a semi-structured clinical interview (Semerari et. al., 2012) adapted from the 
MAS (Semerari et. al., 2003) and based on the same theoretical framework. The MAI is 
intended to be less time consuming to administer than the MAS because metacognitive 
functioning is directly questioned as opposed to retrospectively assessed by standardized 
psychiatric interview. 
 
Floor and ceiling effects (0) and aspects pertaining to interpretability of scores (0) based 
on this data set were not reported. Total score on application of the quality rating was 6 
out of a possible 16, see Table 4. 
 
Metacognitions Self-Assessment Scale (MSAS) 
The MSAS was developed by Pedone and colleagues (2017) in Italy. It is based on the 
work of Semerari and colleagues (2003) and is derived from the MAS and the MAI. The 
MSAS is an eighteen-item self-report measure which is scored using a Likert scale. 
 
It has only been validated in a non-clinical sample. The total score based on quality 
criteria is 5.5 out of 15, given that this is a self-report scale, inter-rater reliability is not 
considered necessary and therefore not scored (meaning total available score is 14, not 
16).  See Table 5 for details of reported psychometric properties. 
 
Metacognitions Questionnaire (MCQ) 
The Metacognitions Questionnaire (Cartwright-Hatton & Wells, 1997) is a 65-item 
questionnaire that was developed to assess beliefs about worry and intrusive thoughts. It 
is based on the Self-Regulatory Executive Function (S-REF: Wells, 2000; Wells & 
Matthews, 1994, 1996) model of psychological disturbance. No papers reporting use of 
this measure with people diagnosed with SSD were identified in the systematic search 
carried out for this review but to fully evaluate the properties of the MCQ-30, which has 
been used with this population, reporting of the original measure validation was 
identified as necessary to provide context. 
 
In terms of concurrent validity, the MCQ was found to be moderately correlated with 
measures of personality traits in a manner posited by the authors in a non-clinical sample 
 18 
(n=104). The authors also reported means and standard deviations for non-clinical 
participants, people diagnosed with obsessive-compulsive disorder, general anxiety 
disorder and clinical controls which demonstrated a pattern of scores with significant 
difference between groups. A total score of 11 out of 14 was attained, see Table 6. 
 
Metacognitions Questionnaire (MCQ-30) 
MCQ-30 is a briefer version of the MCQ that provides a multidimensional measure of 
metacognitive beliefs and monitoring tendencies linked to the general metacognitive 
theory of psychological disorder (Wells & Cartwright-Hatton, 2004). It employs that same 
5 factor structure identified in the validation of the original MCQ and has the advantage 
of being shorter to administer. 
 
MCQ-30 showed good internal consistency and convergent validity, and acceptable to 
good test–retest reliability. Positive relationships between metacognitions and measures 
of worry and obsessive–compulsive symptoms support for the validity of the measure as 
predicted by the metacognitive theory of intrusive thoughts postulated in the S-REF 
model. The authors reported that in terms of interpretability, there were no significant 
differences by sex and there were associations with the trait of pathological worry, 
however the details of this association were not reported. The psychometric properties of 
MCQ-30 are relatively robust with a score of 8.5 out of 14, see Table 7.  
 
Outcomes reported and associations with SSD 
The outcome variables reported to be associated with various aspects of metacognition 
were heterogeneous. There were some results that seem to have been replicated in more 
than one study. The main outcome variables significantly associated with metacognition 
are summarised in Table 8. 
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Table 5: Psychometric properties of MSAS (Pedone et al., 2017) 
Sample N Content 
validity: factors 
Content validity: 
Items 
Proposed factor 
structure 
Support for 
factor structure 
Internal consistency: 
sample size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Non-clinical 6659 3 (1) Experts = yes 
Recipients = no (1) 
5 factor structure  EFA = yes 4 
factors (.5) CFA = 
yes (1) 
N>100 = Yes (1) .72-.87 = Yes (1) Not reported (0) 
 
Table 6: Psychometric properties of MCQ (Cartwright-Hatton & Wells, 1997) 
Sample N Content 
validity: factors 
Content validity: 
Items 
Proposed factor 
structure 
Support for 
factor structure 
Internal consistency: 
sample size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Non-clinical 863 1: own mind 
(.5) 
Experts = yes 
Recipients = yes (2) 
6 factors EFA = yes, CFA = 
5 factors (1.5) 
306 (1) .72-.89 (1) .76-.94 (N=47) (2) 
 
Table 7: Psychometric properties of the MCQ-30 (Wells & Cartwright-Hatton, 2004) 
Sample N Content 
validity: factors 
Content validity: 
Items 
Proposed factor 
structure 
Support for 
factor structure 
Internal consistency: 
sample size 
Internal consistency: 
Cronbach’s  
Test-retest 
reliability: r 
Non-clinical 182 1: own mind 
(.5) 
Experts: yes 
Recipients: no (1) 
5 factors EFA = yes, CFA = 
yes (2) 
N=182 (1) .72-.93 (1) .75 (2) p<.0005 
 
 
Table 8: Summary of associations between metacognition and key outcome variables 
Paper Measure Correlated Outcome Variables 
Abu-Akel et al (2015) MAS-A 
 
High psychopathy (>24 PCL-R) associated with higher overall 
metacognitive function (MF) 
Hamm et al 2012 MF deficits associated with higher negative symptoms 
(PANSS) 
Hasson-Ohayon et al 2015 UownM negative relationship social QoL 
UoM positive relation to social QoL 
SSD associated with deficits in SC & MF  
Lysaker et al 2005 Higher UownM associated with better neurocognition & 
lower emotional withdrawal.  
Higher UoM associated with better verbal memory and less 
emotional withdrawal.  
Higher Mastery was associated with better verbal memory, 
insight and social function  
Higher Mastery associated with less emotional withdrawal 
and paranoia 
Lysaker, Buck et al 2008 MAS total associated with internalised stigma 
Lysaker, DiMaggio et al 
2007 
Low UownM associated with low working memory scores & 
higher disorganization on PANSS 
High UoM associated with better visual memory  
Lysaker, Ringer et al 2012 SSD associated with lower total MAS & poorer scores on 
Hinting Test 
Lysaker, Vohs et al 2014 MAS-A total score able to distinguish between SSD and HIV 
patients 
Poor MF associated with SSD 
Lysaker, Warman et al 
2008 
Higher UownM associated with better mental flexibility in 
tasks 
Higher UoM associated with greater inhibitory control in 
tasks 
Lysaker, DiMaggio et al 
2010 
Higher Mastery associated with higher scores on Social 
Cognition and Object Relations Scale  
Tas, Brown et al 2010 Lower UownM correctly classified 85.2% of patients with SSD 
in logistic regression 
UownM & UoM related to verbal memory and executive 
functioning in SSD, but not in BD 
Higher positive & general symptoms associated with poorer 
MF in SSD  
Trauelson et al 2016 High negative symptoms had poorer MF  
FEP associated with poorer MF than controls  
Vohs, Lysaker et al 2014 Global MF & SC difficulties may be stable features of SSD  
Vohs, Lysaker et al 2015 Higher insight associated higher MF, better vocabulary and 
ToM scores &fewer symptoms 
Mastery predicted clinical insight 
Austin et al 2015 MCQ-30 Elevations in metacognitive beliefs were associated with the 
severity and duration of psychotic symptoms  
Van Oosterhout et al 2013 Negative beliefs about voices associated with negative 
metacognitive beliefs 
Østefjells et al 2015 SSD associated with higher scores on MCQ-30 subscales, 
except positive beliefs about worry  
Negative symptoms predicted lower scores on cognitive self-
consciousness 
Sellers et al 2016 Unhelpful metacognitive beliefs (higher MCQ-30 scores) 
predict negative affect in SSD 
Valiente et al 2012 Psychological wellbeing is compromised in participants with a 
high level of persecutory thinking combined with low levels 
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of cognitive self-consciousness 
Abbreviations: MF – metacognitive functioning; UownM – understanding of own mind; UoM – 
understanding other’s minds; BD – bipolar disorder; FEP = first episode psychosis; SC – social 
cognition; QOL – quality of life; ToM – theory of mind 
 
Discussion 
This review had two main aims. The first was to describe how complex metacognition is 
defined and measured in research with people diagnosed with SSD. Secondly, we wanted 
to describe and evaluate the psychometric properties of the methods used. 
 
Ways of conceptualising metacognition in SSD 
There are two main theoretical models currently used for conceptualising metacognition 
in research with people diagnosed with SSD. These were the modular Metacognitive 
Multi-Function Model (MMFM: Semerari et. al. 2003) and the S-REF information 
processing model (Wells & Matthews, 1994).  
 
The MMFM was developed as a method of quantifying metacognitive acts as elicited in 
psychotherapy. It has been operationalised as modular scales which are applied to 
transcripts of semi-structured interviews such as the Indiana Psychiatric Illness Interview 
(IPII) or the Adult Attachment Interview (AAI) to assess the complexity of understanding 
of one’s own mind, understanding of others’ minds and mastery of this knowledge. Both 
the IPII and the AAI involve asking the interviewee about emotive aspects of their life 
story such as their relationships with their parents (particularly in the AAI), their 
experience of their diagnosis and associated difficulties (in the IPII) and memories of life 
events. This could be a potential challenge for use in research contexts where the 
interviewer and interviewee are unlikely to have a therapeutic relationship and where the 
discussion of this nature might be limited by the quality of the research-participant 
relationship. However, the narrative approach used in the MAS, MAS-A and MAI facilitate 
the generation of more complex material and may have higher ecological validity as 
participants described their thoughts and experiences with relatively little shaping of their 
answers, reducing the chance of biasing or influencing their responses.  
 
The MSAS (Pedone et. al., 2017) is a recently developed and validated tool which may 
provide a bridge between semi-structured interview techniques and more structured 
questionnaires. This method of assessment is a hybrid approach, using the MMFM model 
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but providing a briefer and more structured method of assessment. This tool has only 
been trialled and validated with a non-clinical sample. Application of the MSAS in 
research with peopled diagnosed with SSD would be beneficial. It would be important to 
describe the psychometric properties demonstrated, including the face validity and 
acceptability of the MSAS to participants. 
 
In the development of the MCQ and MCQ-30, hypotheses were generated from the S-REF 
model, clinical observations and extant research. These were tested to refine a tool that 
directly relates to hypothesised constructs. The questions asked in the MCQ and MCQ-30 
relate to one’s beliefs about thinking and worrying. These questions might be more suited 
to research contexts due to their briefer administration time and less emotive content.  
 
It is unclear whether the S-REF and the MMFM derived measures assess the same 
constructs. The MMFM measures purport to assess distinctly reflexive aspects of 
metacognition, encompassing thinking about one’s own mind, those of others’ and 
synthesising that knowledge to adapt and respond in a complex manner to the 
interpersonal environment. The S-REF measures aim to be more attuned to thinking 
about one’s own thinking and the beliefs associated with these cognitions. In terms of 
psychotherapeutic schools of thought, this might more readily correspond to Cognitive 
Behavioural Therapy approaches, whereas the MMFM associated measures seem to be 
more aligned with psychodynamic therapies. 
 
The psychometric status of methods for assessing metacognition 
The quality ratings obtained by application of the criteria used in this review revealed that 
the psychometric properties of methods assessing metacognition in SSD are limited and 
reported inconsistently. Content validity, that is the extent to which the domain of 
interest is captured by the measure was an area of relative strength as all measures were 
conceptually linked to the underpinning theoretical model. However, participant 
involvement in the development of tools was absent.  
 
Factor structure was an area of weakness in both measures but was more robustly 
explored in the development of the S-REF measures. Internal consistency and factor 
structure were not robustly described in the papers reviewed, but this and factor analysis 
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were reported by Cartwright-Hatton and Wells (1997, 2004) in the non-clinical sample 
validation of the MCQ and MCQ-30. Test-retest reliability was insufficiently reported for 
both measures but inter-rater reliability was an area of more robust reporting in the 
MAS-A papers. Inter-rater reliability was not relevant for the MCQ-30 because it is a 
questionnaire.  
 
The extent to which scores on either scale relate to other measures, consistent with 
theoretical hypotheses, was reported more frequently for the MAS-A but was limited for 
the MCQ-30. Floor and ceiling effects was an area of weakness for both measures and 
requires to be addressed. There was some exploration in the literature of problems with 
the Decentration scale on the MAS-A due to scores ranging from only 1-3, meaning that 
floor or ceiling effects are highly likely to be present. Lysaker, DiMaggio and colleagues 
(2010) have excluded this scale from statistical analysis for this reason. Perhaps factor 
analysis of the measure is necessary to address the Decentration factor. Both measures 
would benefit from more reporting regarding the qualitative interpretability of the scales 
and the quantification of what can be considered clinically meaningful change.  
 
Key correlates of metacognition across SSD 
Deficits in synthetic metacognition seem to be a consistent and perhaps distinguishing 
feature in SSD when compared to participants with chronic health challenges (Lysaker et 
al, 2014) and diagnosis of BD (Tas et al., 2010). An association between deficits in 
synthetic metacognition and negative symptoms has been reported in studies using both 
the MAS-A (Hamm et al., 2012) and the MCQ-30 (Austin et al., 2015) and have been 
replicated in studies using the MAS-A (Trauelson et al., 2016), although associations have 
also been found with positive symptoms (Tas et al., 2010). For example, higher 
metacognition as assessed by the MAS-A was predictive of insight into one’s difficulties 
(Lysaker et al., 2015). There appear to be patterns of association that differ across 
subscales on both measures, such as the predictive role of Mastery in insight (Lysaker et 
al., 2005) and social cognition (Lysaker et al, 2010) and the associations between negative 
beliefs about voices and negative beliefs about metacognition (van Oosterhout et al., 
2013) and that higher scores on the MCQ-30 predicts longer duration and greater severity 
of SSD (Austin et al., 2015). These associations warrant further evaluation but highlight 
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the centrality of complex metacognition in understanding SSD and providing effective 
psychotherapies for those experiencing it. 
 
Strengths and limitations of the review 
Metacognition is an important but broad and complex concept of import to psychological 
research and applied practice. This review aims to describe both how complex 
metacognition is measured in research with people diagnosed with SSD and the 
psychometric properties of the methods used. By applying the method used to similarly 
investigate the concept of compassion (Strauss et. al., 2016) this review aims apply 
rigorous methods to enhance the understanding of assessment of complex 
metacognition. 
 
Due to how this area of research has evolved, a conventional systematic review method 
had to be adapted to address the aims of this review. This meant that context had to be 
provided by analysis of papers not detected by the electronic search method. These 
exposed limitations of the validity and reliability of measures used in this area in that they 
reported values for these factors that had not been assessed in the population of interest 
(SSD) and had not been developed with involvement of people diagnosed with SSD. 
 
Recommendations for future research 
Research evaluating synthetic metacognition in people diagnosed with SSD would benefit 
from increased transparency and rigour in the reporting of psychometric properties of all 
measures purported to measure this concept. Both methods may be open to risk of bias 
because the authors associated with the development of both measures are associated 
with most papers included in this review. It is not always clear whether data from the 
same participants have been repeatedly reported in the papers included in this review. 
Future research might benefit from declaring whether participants are from an existing 
dataset and consideration should be given to avoiding bias related to over use of the 
measure by a single research group. 
 
A direct exploration of the extent to which the constructs evaluated by the S-REF and 
MMFM derived measures overlap and differ would be potentially valuable. No study has 
used both measures and explored associations between the two.  
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A potential weakness of the MAS-A, MAS, MAI and MSAS is the confirmation of factor 
structure and the problems identified with the Decentration scale (present in the MAS-A) 
because scores can range from only 1 to 3. The psychometric properties of the measures 
would benefit from further exploration and reporting of exploratory and confirmatory 
factor analysis.  
 
Qualitative exploration comparing the results derived from and the acceptability of 
questionnaire and interview based measures with participants diagnosed with SSD would 
be a valuable addition to the literature. A meta-analysis of associations between outcome 
variables and subscales of both measure may also be timely given the breadth of findings 
already detailed in the literature. 
 
Conclusions 
This review provides an analysis and summary of the conceptual basis and psychometric 
properties of methods of assessing metacognition that have been used in research with 
people diagnosed with SSD. It has identified distinct conceptual and methodological 
variations within the field which may assist researchers in determining which approach 
they wish to employ to interrogate their hypotheses, and can inform practitioners who 
wish to assess metacognition in clinical practice.   
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Plain Language Summary 
Background: 
People who are diagnosed with a Schizophrenia Spectrum Disorder (SSD) are often 
treated in hospital with medication. This is helpful for some people and they can leave 
hospital quickly, but some people don’t respond to this treatment and they stay in 
hospital for a long time or must keep going back. This can be very disruptive; it interrupts 
peoples’ ability to work, learn and have relationships.  
 
We don’t fully understand why some people get better more quickly than others in 
hospital. There is some evidence that psychological therapies can be especially helpful for 
people who don’t respond well to medical treatment for schizophrenia but the ways in 
which these therapies work aren’t clear. We need to understand more about the 
relationships between different thinking and remembering processes which seem to be 
affected in SSD so we can help people to recover. 
 
Autobiographical memory (AM) seems to be affected in SSD and is thought to be vital to 
our personhood because it is the ability to recall our personal experiences. 
Metacognition, most simply meaning to think about thinking (your own and other 
people’s) also seems to be affected. These are both important for psychological therapy 
because therapies often require some ability to recall and reflect on our thinking, 
interpersonal challenges and past experiences.  
 
Aims and Questions: 
This study attempts to find out if it is possible to examine the relationships between 
autobiographical memory, metacognition and recovery when people are experiencing 
psychosis and are in hospital. This hasn’t been tried before using the same methods.  
 
The primary research question asks whether AM and metacognition are correlated in 
people in the acutely experiencing psychosis. The second aim of the study is to explore 
relationships between other factors, such as recovery. Thirdly, the strengths and 
difficulties of the method used in this research will be discussed.  
 
Methods: 
People were interviewed shortly after coming to hospital and again when they were 
nearing discharge. Their AM and metacognition were tested shortly after they were 
admitted to hospital. 
 
Results: 
12 people took part in the study and there was evidence of a robust correlation between 
AM and metacognition. 
 
Limitations: 
A small number of people took part in the study and this means that the results must be 
interpreted carefully. Although there was a correlation, from this project we cannot say 
what the direction of the correlation is. The assessments took a long time to complete for 
most people in the study and many people declined to participate. It might be that the 
study design wasn’t very appealing to people in hospital affected by SSD. But with some 
refinements, this approach could be used with a larger number of participants. 
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Autobiographical memory functioning and response to inpatient treatment for 
people diagnosed with Schizophrenia Spectrum Disorders: Results from a Pilot 
Study 
 
Abstract 
Background: Impairments in executive functioning and autobiographical memory (AM) are 
common in people with schizophrenia spectrum disorders (SSD). There is a need for 
greater understanding of how neurocognitive factors such as these relate to recovery. This 
is important because improving treatments requires better understanding of the 
psychological process involved in recovery from SSD. Aims: We aimed to determine the 
feasibility of assessing AM and metacognitive functioning in the acute phase of psychosis 
during inpatient admission. Relationships between neuropsychiatric measures and 
autobiographical memory were explored with a view to refining the use of this assessment 
battery with participants who are acutely psychotic. Methods: Twelve people diagnosed 
with a schizophrenia spectrum disorder were recruited from adult inpatient psychiatric 
wards shortly after admission. They completed the Autobiographical Memory Interview, 
Indiana Psychiatric Illness Interview, Hayling Sentence Completion Task, BMIPB Story Recall 
Task and the Positive and Negative Syndrome Scale (PANSS) interview in baseline 
assessment. Four participants were re-tested prior to discharge and rated their own 
recovery using the Questionnaire on the Process of Recovery. Ward clinicians also rated 
recovery in terms of symptom remission for eleven of the participants. Results: A 
moderate correlation between metacognition and semantic AM (r=.716) was identified at 
baseline. Correlations of moderate strength were identified between clinician ratings of 
recovery and metacognition (r=-.725) and PANSS (r=.877) scores at baseline assessment. 
Conclusions: The study faced difficulties recruiting sufficient numbers of eligible 
participants at baseline and retaining them to allow for follow up assessment. Hence, the 
results are preliminary but the data do suggest possible neuropsychological correlates of 
recovery from acute psychosis. If the recruitment and retention issues could be addressed, 
this paradigm could be applied to a larger sample to test the findings of this pilot study.  
 
Key words 
schizophrenia spectrum disorders; metacognition; autobiographical memory; recovery; 
feasibility study  
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Introduction 
There is an established association between schizophrenia spectrum disorders (SSD) and 
impairments in memory and executive functioning, including impairments in episodic 
memory, over-general autobiographical memory and poor mentalising (Watson et. al., 
2012). It is unclear how cognitive factors such as these change alongside aspects of 
recovery, such as reduction in symptom burden and duration of admission to inpatient 
psychiatric services. 
 
Memory and executive functioning are important consistently identified areas of 
disruption of functioning in SSD (Berna, et. al., 2016). These deficits predict variance in 
recovery (Green, Llerena & Kern, 2015). However, the relationship between impaired 
autobiographical memory functioning in SSD and experiences such as symptom 
exacerbation and disturbed sense of self are poorly understood (Wood, Brewin, & 
McLeod, 2006). 
 
Metacognition is also found to be impaired in SSD and like autobiographical memory, is 
thought to be important for understanding the experience of SSD and in psychological 
treatment (Lysaker et. al., 2007). Metacognition allows us to construct narratives about 
ourselves and the world and this helps us navigate new challenges (DiMaggio et. al., 
2012). A breakdown in the ability to access personal memories from the past leads to an 
impoverished mental life and possibly more difficulty with meeting interpersonal and 
practical challenges. Autobiographical memory (AM) underpins the sense of a continuous, 
unified sense of self (Mishara et. al., 2014) and disturbances AM and sense of self is a 
common problem in SSD (for example, Danion, et. al., 2005). This ability to recall life 
events and make sense of feelings and experiences is important for many therapeutic 
interventions (Linington, 2010). 
 
Autobiographical Memory in SSD 
The episodic memory system retains knowledge of recent episodes over varying retention 
intervals measured in minutes and hours up to decades (Tulving, 2002). The AM 
subcomponent of episodic memory retains knowledge of personal events and facts over 
much longer retention intervals measured in weeks, months, years and across the life 
span. There is meta-analytic evidence that, along with impairments in episodic memory 
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and executive functions, AM is impaired in people diagnosed with SSD, with moderate to 
large effects seen for features such as specificity of recall, richness of detail, and the 
intensity of subjective re-experiencing (Berna, et. al., 2015).  
 
AM is intrinsic to a preserved sense of self and personal identity (Riutort, et. al., 2003) 
and entails the ability to recall personal events and facts pertaining to one’s life, such as 
name, where one attended school or first job. It is commonly sub-divided into personal 
semantic memory (facts about the self) and personal episodic memory (event memory). 
Tamlyn and colleagues (1992) investigated autobiographical memory in four people 
diagnosed with schizophrenia using the Autobiographical Memory Interview (AMI; 
Kopelman, et. al., 1989) and concluded that it was impaired across the life span, with 
relative sparing of early memories. Feinstein and colleagues (1998) used the same 
paradigm with 19 individuals with schizophrenia and 10 healthy controls and identified a 
U-shaped distribution of scores. That is, memories for childhood and recent events were 
relatively preserved but recall was much poorer for the period of symptom onset, early in 
adult life. It is theorised that this deficit may reflect disruption in encoding or acquisition 
processes (Elvevåg, Maylor & Gilbert, 2003). The evidence indicates that people 
diagnosed with SSD demonstrate an over-general style of recall for personal life events 
but findings regarding the pattern of recall over time are inconsistent (Wood, Brewin, & 
McLeod, 2006). 
 
Using a Remember, Know, Guess paradigm, Danion and colleagues (2005) compared AM 
recollection of people diagnosed with SSD to that of control participants and found that 
AM recollection was poorer in terms of frequency and consistency across the life span. In 
addition, SSD participants were significantly more likely to provide a Guess response. This 
may be linked to the finding that over-general recall has been observed in people 
diagnosed with SSD. This lack of specificity may be a compensation for the absence of 
confidently-recalled AM (Ricarté, et. al., 2014). Therefore, there is converging evidence 
that AM is impaired in SSD and that this deficit is manifest in both personal semantic and 
episodic memories and that these difficulties are consistent with a disrupted sense of self 
in schizophrenia (Riutort et. al., 2003). It is not yet known but it can be theorised that 
disturbances in autobiographical memories affecting sense of self in SSD will be 
associated with metacognitive abilities, because metacognition facilitates the experience 
of complex thinking about the self and others, and the use of this information to solve 
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problems (Pec, Bob & Lysaker, 2015). Pothegadoo and colleagues (2017) reported data 
which suggest that cueing strategies can improve AM recall in SSD, which identifies this as 
a promising target of remedial therapies. 
 
Metacognition, Mentalising and Self-Awareness in SSD 
Metacognition, mentalising, self-awareness and Theory of Mind (ToM) all refer to a 
person’s ability to “think about thinking”, about both their own minds and the minds of 
others (Lysaker, et. al., 2007). Awareness of one’s strengths and difficulties is a form of 
metacognitive knowledge that can recruit cognitive resources to a specific task and allows 
a person to identify what external resources they might need to draw upon to function 
effectively (Flavell, 1979). An inability to form complex representations of the mind of the 
self and others is associated with impaired insight and a higher burden of negative 
symptoms in SSD (Lysaker, et. al., 2017). ToM refers to relatively discrete metacognitive 
acts, such as reading emotional cues in facial expressions or perceiving sarcasm (Bora & 
Pantelis, 2016). Synthetic metacognition refers to a more complex understanding of 
minds and the ability to use this knowledge in inter- and intrapersonal problem solving. 
Lysaker and colleagues (2005) identified associations between metacognition, symptoms, 
quality of life, neurocognition and poorer awareness of illness in SSD. For example, 
understanding of one’s own mind, others’ minds and the ability to use this knowledge to 
solve problems was associated with better performance on several dimensions such as 
social functioning and insight into difficulties. These findings combined with evidence of 
impaired awareness of cognitive deficits in SSD (Cella, et. al., 2014) and an association 
between metacognition, insight and problem solving in SSD, making it a promising target 
for treatments (Chan et al., 2004). 
 
Recovery in Schizophrenia Spectrum Disorders 
Recovery in schizophrenia is variable with many potential outcomes, the indicators of 
which are not yet well understood (Liberman & Kopelowisz, 2009). Within the prevailing 
biomedical framework of understanding, recovery is predominantly defined in terms of 
symptom remission and factors such as frequency of hospital admission or duration of 
hospital stay (National Institute for Health and Clinical Excellence, 2010). Conceptualising 
recovery in this way neglects other salient aspects of functioning and it seems that for 
individuals experiencing SSD, psychosocial factors are identified as more important in 
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their recovery than neuropsychiatric factors (Morrison, et. al., 2013). Clinicians, 
researchers and people living with schizophrenia may conceptualise recovery differently 
(Jääskelainen et. al., 2013) and views regarding what constitutes recovery vary between 
people diagnosed with SSD. Reliably assessing the multi-factorial concept of recovery is 
difficult and a method of doing so has not yet been established, particularly in the acute 
phase of distress such as admission for psychiatric stabilisation.  In this study, the 
feasibility of collecting subjective ratings of both symptom remission and psychosocial 
factors was examined. 
 
In summary, disruptions to sense of self are consistently identified in people diagnosed 
with SSD but whether AM deficits underpin disruptions to metacognition is not yet 
known. Recovery is heterogeneous in schizophrenia spectrum disorders in terms of how it 
is defined and how it is realised; it is not determined by medication and symptom 
remission alone. To design effective treatments, it is important to understand the 
psychological processes of recovery in SSD. This exploratory study pilots a novel method 
of examining correlations between AM, metacognition and recovery in SSD and seeks to 
answer questions regarding the feasibility of the methods used. 
 
Aims 
This exploratory study trials a method of examining the relationships between 
autobiographical memory, metacognition and executive functioning factors during the 
acute phase of SSD. Previous studies have compared groups of people with poorer versus 
better recovery which may be a less robust method of evaluating these factors. Data 
collected allows for exploration of correlations between variables and can provide 
answers to feasibility questions such as recruitment and retention rates and pilot 
questions such as, can this method be applied to research with the sample population? 
By answering these questions, we can inform the generation of hypotheses and 
methodologies for future research.  
 
Hypothesis 
It is hypothesized that performance in the Autobiographical Memory Interview and 
metacognition as measured by the adapted Metacognitive Assessment Scale will be 
correlated at baseline assessment. 
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Design & Methodology 
This research study employs a repeated measures design allowing for both within and 
between subjects’ analyses. In addition to attempting to answer the hypothesis, this 
study has a primary focus on addressing feasibility questions such as whether it is 
possible to recruit and retain participants to test the hypothesis and whether AM and 
metacognition can be examined using the tools selected. Pilot questions such as whether 
this protocol can be successfully applied to this population are answered and practical 
facilitators and barriers are discussed in this exploratory study.  
 
Data were collected from people diagnosed with SSD who were admitted to inpatient 
wards for acute care.  Data collection was carried out over three months between March 
2017 and June 2017. 
 
Ethics & Governance 
Ethical approval was provided by NHS West of Scotland Research Ethics Committee (see 
Appendices 2.2 & 2.3). Approval was also gained from NHS Greater Glasgow and Clyde 
Research and Development Department and each sector’s Clinical Governance groups. 
 
Participants 
Participants 18 years or older with a diagnosis of a SSD were recruited from inpatient 
adult mental health wards in NHS Greater Glasgow and Clyde.  People with a recognised 
cognitive deficits such as a Dementia or Learning Disability or a history of head injury with 
loss of consciousness were excluded. Eligibility was determined through discussion with 
the referring professional and the initial interview with the participant. Intoxication with 
alcohol or illicit substances at the time of testing and any illicit substance use within the 
preceding 24 hours also led to exclusion. In addition, those without adequate command 
of English were excluded, as were any participants that were not able to give informed 
consent at the time of assessment.  
 
Recruitment 
Screening discussions were held between the ward staff and the researcher to identify 
eligible participants. Once identified, a staff member discussed the project with the 
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service user, provided them with an information sheet (see Appendix 2.4), and gained 
verbal consent for the researcher to meet with them. Written informed consent was 
obtained prior to participation (see Appendix 2.5). 
 
All participants had been admitted to inpatient wards in the NHS Greater Glasgow and 
Clyde Health Board. One participant was detained in an intensive psychiatric ward which 
is a locked, medium secure ward. Recruitment sites were located across the city of 
Glasgow; in the North East sector there are six wards, located in two hospital sites and 
recruitment was attempted in all but one of these wards. In the South there are four 
wards, recruitment was active in one of these wards and in the North West there are four 
wards, recruitment was active in one of these. 
 
Sample Size 
We wanted to determine if it was feasible to recruit people diagnosed with a 
schizophrenia spectrum disorder at the time of admission to inpatient care and to 
complete measures of autobiographical memory functioning and metacognition. This is 
an exploratory study piloting a paradigm investigating patterns of recovery and 
interactions between variables (measures of AM and metacognition) that can be used to 
make power estimations for future trials (Lancaster, Dodd & Williamson, 2004). The study 
seeks to address both feasibility and pilot questions of relevance to further research 
(Arain et. al., 2010). 
  
Measures 
The Autobiographical Memory Interview (AMI: Kopelman, Wilson & Baddeley, 1989) tests 
a subject’s recall of facts from their life history over three broad life stages: childhood, 
early adult life and recent incidents. The AMI measures personal semantic and episodic 
memory at different time points by asking participants to recall semantic information 
(such as their home address) and episodic memory (by recounting a memory of a 
personal incident). Similar questions are asked for each life stage allowing for 
measurement of the pattern of AM over three time points. This test is not dependent on 
the individual’s general knowledge or interest in current affairs.  The AMI has high inter-
rater reliability and the score will provide a comparison for better or poorer AM within a 
range of functioning because it has been validated and normed with clinical populations.  
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The Metacognition Assessment Scale-Abbreviated (MAS-A: Lysaker, et. al., 2005) has 
been developed for use with individuals experiencing psychosis and has been extensively 
used in the literature (e.g. Abu-Akel & Bo, 2013; Pec, Bob & Lysaker 2015).  The MAS-A 
will be applied to transcripts from the Indiana Psychiatry Illness Interview (IPII: see 
Lysaker et. al., 2002 for paradigm). The IPII is designed to elicit a narrative from the 
individuals about themselves and about illness. This measure is unique in that it produces 
a narrative of the self in which evidence of metacognitive acts can be described 
spontaneously with minimal scaffolding which minimises cueing effects and therefore 
should produce a more accurate assessment of synthetic metacognitive capacity (Lysaker 
et. al., 2010).  The MAS-A is subdivided into four scales: Self Reflectivity, which is briefly 
defined as the comprehension of one’s own mental state; Understanding of Others Mind, 
or the comprehension of other’s mental states; Decentration, which is the ability to 
understand that others have independent motives; and Mastery, which is the ability to 
use mental state information to accomplish cognitive tasks or cope with psychological 
distress.  Metacognition is thought to exist on a continuum of function, so the MAS-A is 
scored on an ordinal scale with higher scores denoting greater complexity.  
 
The Positive and Negative Symptom Scale (PANSS; Kay, Fizsbein & Lindenmayer, 1987) is 
a widely used 30-item scale examining a range of symptoms commonly observed in 
patients with psychotic disorders.  This measure will be administered to provide an 
assessment of overall symptom burden subdivided into positive, negative and general 
symptoms.  
 
The Brain Injury Rehabilitation Trust (BIRT) Memory and Information Processing Battery 
story recall task (BMIPB; Coughlin, Oddy & Crawford, 2007) will be used to provide a 
measure of general memory functioning.  The BMIPB provides a repeatable assessment of 
memory (recall and recognition) and speed of processing. The Story Recall task tests 
immediate and delayed recall abilities. This subtest has been shown to have high inter-
rater reliability; r=0.9. 
 
The Hayling Sentence Completion Test (HSCT, Burgess & Shallice, 1996) consists of two 
sections of fifteen sentences and measures response initiation and inhibitory control. In 
the first section participants are asked to produce a single word to complete a sentence. 
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In the response inhibition condition participants are asked to produce a word that is 
contextually nonsensical to complete the sentence. The HSCT has been used extensively 
to assess executive functioning in people with schizophrenia (e.g. Chan et al., 2004; 
Joshua et al., 2009). 
  
The Brenner Scale of Clinical Change in Schizophrenia (Brenner Scale: Brenner et. 
al.,1990) is a clinician rating used to measure the perceived degree of symptom 
remission, referred to here as clinician rating of recovery.  This uses a Likert scale from 
Level 1 – Clinical Remission to Level 7 – Severely Refractory.  Each level on the scale is 
accompanied by a brief operational definition of its meaning in terms of response to 
antipsychotic medication and degree of supervision required in social, personal and 
vocational domains of functioning. 
 
The Questionnaire on the Process of Recovery Scale (QPR) assesses patient’s perception 
of individual recovery (Neil, et. al., 2009).  This instrument was developed in collaboration 
with service users in the UK and has been validated for use within a population with 
similar demographic characteristics as those recruited to this study.  The QPR is a 22-item 
measure that is divided in to intrapersonal factors and interpersonal factors.  Neil and 
colleagues (2009) evaluated the validity of the QPR and reported that it has good internal 
consistency, construct validity and reliability. As such, it is suitable for use as a clinical and 
research tool to assess and promote recovery in psychosis.  It can be used as a one-off 
measure or repeated over time. 
 
Procedure 
Baseline assessment (T0) 
Following the collection of informed consent and demographic information participants 
first completed the Hayling Sentence Completion task, this was followed by the 
immediate recall component of the Story Recall task. The Indiana Psychiatric Illness 
Interview was then administered; this section of the interview was recorded and then 
transcribed. This was followed with the delayed component of the Story Recall task, 
ensuring that this was completed within 40 minutes (± 2) of the immediate task, before 
completion of the Autobiographical Memory Interview. Finally, the Positive and Negative 
Syndrome Scale semi-structured interview was administered. Participants were offered 
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breaks between assessments and on three occasions the testing was carried out over 
more than one session; on one occasion this was due to visitors arriving to see a 
participant and on two occasions this was because participants were too affected by 
symptoms to continue to engage in the assessment. In all instances the assessment was 
completed the following day. 
 
Follow up assessment (T2) 
As in the first assessment, the Sentence Completion task was administered first, followed 
by immediate Story Recall. The AMI and PANSS were then administered, with delayed 
Recall after 40 (± 2) minutes. The participant then completed the QPR. Following the 
assessment, the Brenner Rating of Clinical Change was completed by a staff member with 
knowledge of the participant. If a suitable person was not available on the day of the 
follow up assessment, efforts were made to complete this scale on the next possible date. 
 
IPII coding 
The IPII was coded using the Metacognition Assessment Scale - Abbreviated (MAS-A; 
Lysaker et al., 2005) as previously described. Training in the application of the MAS-A to 
the IPII was provided by Professor Paul Lysaker via Skype. A subset of four transcripts 
were scored by Lysaker’s team to ensure reliability. The external rater was blind to details 
and status of the participant but the primary researcher was not. 
 
Results 
Feasibility & Recruitment 
Thirty-nine individuals were screened, eleven were excluded at this stage, based on 
current dependence on alcohol or non-prescription drugs (n=4), significant risk of 
violence (n=2), disputed diagnosis awaiting second opinion (n=1) and too long since 
admission to hospital (n=4). Twenty-eight people were approached, fourteen of whom 
declined to participate. Reasons identified were the person was unable to complete 
informed consent due to symptom severity (n=4), insufficient English language ability 
(n=1), declined due to concerns about recording part of interview (n=5), declined due to 
concerns about ‘recovering traumatic memories (n=1) and declined without giving a 
reason (n=3).  
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Fourteen people were recruited to the study and completed informed consent 
procedures, of these, twelve people completed baseline assessment. One person 
withdrew from the study due to concerns about confidentiality and impact of 
participation on treatment within the ward and another was unable to complete the 
baseline assessment. Participation took place over one or two sessions, depending on the 
needs of the participant and ward restrictions such as meal times or visiting hours. Follow 
up participation took place over a single session. 
 
All but one of the participants who completed baseline assessment were recruited from 
the North-East sector. One participant admitted to a ward in the South sector completed 
baseline and follow up assessment and one participant admitted to a ward in the North 
East completed informed consent but was unable to complete baseline measures.  
 
Four people completed the entire follow up assessment, eight people were lost to follow 
up for all measures except the Brenner Rating Scale of clinical change during admission 
(completed by clinical staff). Reasons identified for attrition were the speed with which an 
individual was discharged following admission (n=5) and when follow up appointments 
had been arranged when discharge was imminent, contact details were incorrect or 
messages were not responded to meaning that the assessment could not be conducted in 
the community despite plans to do so (n=3).  
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Figure 1 - PRISMA recruitment flow chart 
 
 
Demographic Information  
At the time of assessment, all participants were detained under the Mental Health (Care 
and Treatment) (Scotland) Act 2003. Ten participants were male and two were female, 
the mean age at participation was 40.8 ±11.3 years. All participants had a diagnosis of a 
schizophrenia spectrum disorder, eight were diagnosed with paranoid schizophrenia, 
three with a psychotic episode and one with psychotic depression and paranoid 
schizophrenia. All participants were prescribed neuroleptic medication and all were 
detained in hospital at first assessment. 
 
Screened for eligibility, n=39 
Approached by researcher, 
n=28 
Recruited to study, n=14 
Completed T0 assessment, n=12 
Clinician rated 
symptom remission, 
n=11 
Completed T2 
assessment, n=4 
Excluded from study, n=11: 
 Substance-dependent, n=4 
 Risk of violence, n=2 
 Disputed diagnosis, n=1 
 Too long since admission, n=4 
  
Declined to participate, n=14: 
 Symptoms too severe, n=4 
 Insufficient English, n=1 
 Did not consent to recording of 
interview, n=5 
 Concerns about traumatic memories, 
n=1 
 No reason given, n=3 
Did not complete T0 assessment, n=2: 
 Symptoms too severe, n=1 
 Withdrew from study, n=1 
Lost to follow up, n=8: 
 Discharged too soon, n=5 
 Lost contact in community, n=3 
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Table 1 – Summary of descriptive data 
Descriptive data for all baseline assessment measures 
 Mean (SD) Median (IQR) Descriptor 
Age 40.83 (11.34) 45 (27.50-50.75)  
Days in hospital at T0 11.00 (7.14) 9 (8.25-13.75)  
Immediate story recall 10.67 (8.22) 11.5 (2.25-18.75) -2 SD 
Delayed story recall 7.58 (7.46) 6 (.25-13.00) -1 SD 
Hayling raw score test A 22.66 (18.12) 16.5 (12-30)  
Hayling raw score test B 56.08 (25.27) 63 (29.75-69.75)  
Hayling categorical score 3.08 (2.07) 2.5 (1-6) Abnormal  
AMI semantic total 46.08 (11.63) 51 (38.63-53.00) Definitely abnormal 
AMI episodic total 13.00 (6.11) 14 (8.25-17.00) Probably abnormal 
MAS-A total 9.58 (4.86) 9.25 (4.88-13.75)  
Understanding one’s own 
mind scale  
4.00 (2.15) 3.5 (2-5)  
Understanding others minds 
scale 
2.50 (1.09) 2 (1.63-3.38)  
Decentration scale 0.63 (0.61) 0.5 (0-1)  
Mastery scale 2.54 (2.05) 2.25 (1.00-4.13)  
PANSS total 75.67 (16.24) 72.5 (61.50-91.25) Moderate overall 
symptom severity 
PANSS positive scale 20.42 (6.49) 19.5 (14.75-25.75)  
PANSS negative scale 18.33 (7.66) 16 (12.25-25.75)  
PANSS general scale 36.92 (7.35) 36 (30.00-44.25)  
 
Statistical Analyses  
Non-parametric correlations were explored using the Spearman’s Rho test. Relationships 
between variables at baseline were explored and correlations between these and 
symptom remission were tested. 
 
Patterns of autobiographical memory recall were compared to those reported in key 
comparison papers and post hoc analysis using Wilcoxon signed-rank tests was carried 
out. 
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Main Findings 
Significant correlations between measures at baseline 
The null hypothesis can be tentatively rejected in this study because a moderate 
correlation between MAS total score and AMI total Personal Semantic (r=.716, p<.05) was 
identified at baseline. A correlation was also found between MAS total and PANSS total 
scores (r=-.688, p<.05) and this correlation held between MAS total score and PANSS 
negative symptom subscale (r=-.636, p<.05). The MAS decentration subscale was highly 
positively correlated with PANSS negative subscale (r=.877, p<.005) which violated 
expectations. 
 
Correlations between baseline measures and clinician-rated recovery 
AM functioning at baseline was not correlated with clinician-rated symptom remission. 
However, there was a significant correlation in the direction we would expect between 
total MAS-A score and rating of symptom remission (r = -.725) meaning that poorer 
remission correlates with low scores on the MAS-A. The strongest correlation was 
identified with the mastery scale (r = -.785) and the understanding one’s own mind scale 
also correlated with remission (r = -.654); the remaining subscales (other’s minds and 
decentration) were not correlated with remission.  
 
Total PANSS score was correlated with remission rating (r =.877) indicating that higher 
symptom burden is associated with poorer clinician-rated recovery. The correlation was 
significant for the general (r =.687) and negative (r =.607) symptom subscales, no 
correlation was identified between the positive subscale and remission. 
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Table 2 - Correlations between scores and clinician rating recovery 
Variable Clinician rating of recovery 
AMI personal semantic score -.191 (p = .575) 
AMI personal events score -.425 (p = .193) 
Total MAS-A score -.725 (p = .012)* 
Self  -.654 (p = .029)* 
Other -.063 (p = .854) 
Decentration -.501 (p = .116) 
Mastery -.785 (p<.001)* 
Total PANSS score (T0) .877 (p<.001)* 
Positive scale .505 (p = 113) 
Negative scale .607 (p = .048)* 
General scale .687 (p = .019)* 
 
Pattern of AM recall 
The mean total AMI performance scores indicated that ability to remember personal 
semantic information was in the “definitely abnormal” range (M = 46.08, SD = 11.63) and 
that ability to recall personal events was in the “probably abnormal” range (M = 13, SD = 
6.11). For personal semantic information, there were no statistically significant 
differences by lifetime period (childhood median = 17.08, IQR = 15.63-18.38; early 
adulthood median = 14.46, IQR = 9.75-18.88; recent median = 14.54, IQR = 12.75-18.88). 
Post hoc analysis with Wilcoxon signed-rank tests found no significant difference between 
childhood and early adulthood (Z = -.85, p = .398), early adulthood and recent (Z = -.28, p 
= .783) nor childhood and recent (Z = -.67, p = .503). 
 
Table 3 –Comparison of pattern of AM recall over time 
Mean AMI performance (and standard deviations) 
  Childhood Early Adulthood Recent History 
Personal Facts A 12.55 (3.89) 10.83 (4.74) 15.9 (2.51) 
 B 17.08 (1.41) 14.46 (6.25) 14.54 (6.10) 
Personal Events A 4.65 (2.31) 4.3 (2.32) 6.35 (1.72 
 B 5.00 (2.04) 3.92 (2.87) 4.08 (2.31) 
A – McLeod, Wood and Brewin (2007) schizophrenia sample, B – this sample 
In contrast with the findings of Feinstein and colleagues (1998) and McLeod, Wood and Brewin (2007) 
a U-shaped pattern of autobiographical recall was not observed in this sample. 
 
 47 
Discussion 
Even within this small sample of data, there are signals that indicate correlations of 
moderate strength between metacognition and semantic AM, and between total 
symptom burden and metacognition. Of interest, negative symptom burden was 
correlated with metacognitive scores which agrees with previously reported findings 
(Nicolò, et. al., 2012). Unexpectedly, the decentration subscale of the MAS-A was highly 
correlated with negative symptom scores, indicating that higher negative symptom 
burden is correlated with difficulties in seeing the self and one’s behaviours at the centre 
of the world. This could be an idiosyncratic result related to the small sample size, and as 
with all the relationships identified, warrants further exploration with a larger sample to 
confirm the strength of the findings. 
 
There was a significant correlation between metacognition at baseline and clinician-rated 
symptom remission. Due to the small sample and design of the study, no conclusions can 
be drawn regarding the direction of causality in this relationship: it may be that people 
with who demonstrate higher metacognitive skills are more likely to be perceived as 
having remitted symptoms by clinicians or it may be that metacognition predicts 
remission of symptoms. The results suggest that metacognition, in particular 
understanding of one’s own mind and mastery, correlate with remission.  These findings 
warrant further investigation to better delineate relationships and explore causality.  
 
As previously discussed, there is some evidence of loss of AM recall for the early adult 
period in SSD and it has been postulated that this indicates a deficit in recall for the time 
in life when SSD difficulties commonly emerge. It could be reasonably expected that this 
sample would show evidence of a similar curve in the data, however there was highest 
recall of childhood personal facts and events. There was no corroboration available for 
the memories described in the AMI, some of which could be queried as confabulations or 
inaccuracies, particularly in participants who demonstrated high levels of positive 
symptoms. 
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Recruitment & Retention 
It is possible that a briefer assessment would have been more acceptable to potential 
participants and it may be that being asked about one’s memories was perceived as too 
intrusive, presenting a barrier to participation. 
 
The higher recruitment and retention rates in the North-East sector are likely to be 
related to the researcher being employed in that sector. Established relationships with 
nursing staff seemed to be an important factor in supporting recruitment. A practical 
factor that might have improved retention rates would have involved a formal method of 
communication between nursing staff and the researcher. If the researcher had been able 
to attend weekly multi-disciplinary meetings or if a member of staff had been identified 
to fulfil a liaison role, it is possible fewer people would have been lost to follow up due to 
discharge. 
 
Clearly identifying the researcher’s role and level of independence from the clinical team 
should be considered. The researcher worked in some of the recruitment wards, was an 
NHS employee and was sometimes introduced to potential participants as “the 
psychologist” which occasionally led to confusion and had to be clarified by the 
researcher. Future studies might have greater recruitment and retention success if 
researchers have one defined role within the ward and can regularly work with staff and 
patients in that capacity. Time invested in building rapport with ward staff and patients 
was important to achieving the sample size that was ultimately attained. 
 
Limitations 
All conclusions derived from the analysis of the data are significantly limited in their 
generalizability and power by the small sample size. It was not possible within the time 
allocated to collect data from a large enough sample to generate statistical power in the 
analysis. Further to this, it was not possible to carry out an analysis of performance across 
baseline and second assessments due to the significant number of participants lost to 
follow up. The small sample also precluded analysis of neuropsychological tests used in 
the assessment. Depending on the hypothesis under examination, the assessment could 
be made briefer, and therefore more acceptable to participants, by excluding one or 
more of these tools. 
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The primary researcher was not blind to the status of participants and although 
calibration was attempted at the training stage with all measures, only a sub-set of data 
was double rated and compared.  
 
Due to the inability to check the veracity of information provided in the AMI, all data 
were treated as valid memories and scored in accordance with the AMI manual. Future 
studies could benefit from controlling for potential confabulation by obtaining 
corroboration for memories where possible. In addition, there was no formal test of 
effort used in this study meaning that disengagement or lack of motivation has not been 
controlled for in this study. 
 
Future considerations 
Enrolling people who are experiencing acute psychosis is challenging because of both 
symptoms and the legal context of treatment which can impair communication and the 
development of rapport. Individuals may find it difficult to complete consent or may not 
wish to because they are suspicious about the nature of the research, this may be 
because they are concerned that whether they engage will influence staff thinking and 
decisions made about their care, despite the researcher’s assurances to the contrary. 
A third of people approached agreed to participate in the study and reasons for declining 
to participate were related to the recording of the IPII, which was required for the 
application of the MAS-A, and to discussing personal life events. It may be that the subset 
of people who did agree to participate are different to those who declined and exploring 
this might be useful in future trials. 
 
To substantiate some of the preliminary findings of this study regarding associations 
between metacognition, symptom burden and recovery, further studies with larger 
sample sizes are necessary. To address some of the issues discussed here future 
researchers may wish to consider issues such as bias in recruitment, retention to follow-
up and corroboration of memories . A larger sample size may allow for further analysis to 
explore the nature of these tentative findings. 
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Conclusions 
Whilst we provide preliminary evidence of an associations between metacognitive ability 
and recovery and symptom burden and recovery, there are many methodological 
limitations which may limit the generalisability of these findings. Nonetheless, this has 
allowed us to pilot and evaluate the research methods used and to identify ways that 
research into the study hypotheses could be progressed in the future. The method 
showed promise but practical challenges that affected recruitment and retention require 
to be addressed. 
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8. Inter-rater reliability: This refers to the reliability of observations across raters on 
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Appendix 2.4: Participant Information Sheet 
 
 
 
 
 
 
 
 
Invitation to Participate in a Research Project 
 
Autobiographical memory functioning and recovery in psychosis 
 
We would like to invite you to take part in a research study. Before you decide, you need 
to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if you 
wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
Who is conducting the research?  
The research is being carried out by Ms Sarah Breustedt who is a Clinical Psychologist in 
training from the University of Glasgow. The research is being supervised by Professor 
Hamish McLeod from the University of Glasgow. Dr Laura Raymond, Dr Allison Blackett and 
Dr Ian Mark Kevan, who are all Consultant Clinical Psychologists, are supporting the 
research in inpatient psychiatric wards in NHS Greater Glasgow and Clyde. 
 
What is the research about?  
This study is designed to investigate autobiographical memory, which is how people 
remember events that have happened to them in their lives. In particular, we are looking 
at this with people who have been diagnosed with psychosis and have been admitted to 
inpatient mental health services. This kind of research will contribute to understanding of 
the needs of people with psychosis, and to developing new ways that aim to help people 
recover. The study is being undertaken as part of the fulfilment for an academic 
qualification (Doctorate in Clinical Psychology).  
 
Who is being asked to take part?  
We are asking people who are involved in currently inpatients in mental health services 
who also have a diagnosis of schizophrenia and other similar disorders, to take part in the 
study.  
 
Why have I been asked to take part?  
A member of the mental health team responsible for your care (e.g. Psychiatrist, Clinical 
Psychologist or Psychiatric Nurse) has suggested that you might be eligible to take part in 
this study.  
 
What do you mean by the term “autobiographical memory”?  
“Autobiographical memory” refers to a person’s memory of events that have happened in 
their own lives. These can be memories of specific events or of more general periods in a 
person’s life, such as childhood and growing up.  
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What are you asking me to consent to?  
If you consent to participate, you will meet with a researcher on the ward to complete an 
interview and some memory tasks. The researcher will also look at your case notes to 
collect information about your age, diagnosis, duration of illness and medications. Also, a 
staff member who is involved in your care will provide information relating to your 
recovery.  
 
What does taking part involve? 
If you decide to take part in the study, you will be asked to: 
Let the clinician who told you about the study know that you are happy to learn more 
about the study and they will pass your details to Sarah Breustedt who will visit you on the 
ward.  
 
Sarah will give you more information about the study, answer any questions you have and 
if you still would like to take part, she will arrange an appointment time with you. The 
appointments will all take place in the inpatient ward where you are staying. 
Before you begin the interview, Sarah will ask you to sign a consent form to say you agree 
to take part in the study 
 
Your interview will last around one hour and will be an informal discussion followed by two 
short thinking tasks. Sarah will ask you some questions about your life before coming in to 
hospital and she will ask you about how you are feeling now, including any symptoms you 
are experiencing. She will also ask you to try two short tasks testing your memory and your 
ability to think about thinking 
 
If you are happy to continue in the study, Sarah will arrange to meet with you again in 
around two weeks’ time and you will repeat some of the tests. This session will be a bit 
shorter. If you aren’t in the hospital anymore, Sarah will offer to meet you somewhere 
suitable, such as a local clinic. The cost of you travelling there by taxi or public transport 
will be paid for by funds from the University of Glasgow. 
 
You will be able to take breaks during the sessions if you would like to and you can decide 
to stop participating in the study at any time. You don’t have to give a reason for this. 
 
The interviews will be audio-recorded and later written down but with information that 
could identify you removed. The interviews may prompt you to remember positive 
experiences as well as upsetting experiences but we will not deliberately ask you any 
embarrassing or upsetting questions. You do not have to discuss any of the experiences 
that come to mind if you do not want to.  
 
Will my information be confidential?  
All the information that you provide will be treated as confidential. This means that all the 
information will only be identified by a code and not by your name. We will keep all the 
information safe and anonymous. This means that it will not include your name, the names 
of other people, schools, or jobs that you may mention, or any other information which 
could identify you. Only the researcher who interviews you will hear the original recording. 
Once the interview is written down, the recording will be destroyed. Quotes from your 
interview might be included in the study when it is published, but these quotes will have 
any identifying information taken out and your real name will not be used so that no one 
(other than the researcher) will know that the quote is something you said.  
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With your permission, Sarah will inform the member of the mental health team who 
referred you that you are taking part in the study. If you share information that makes 
Sarah concerned for your safety or the safety of other people, she will have a duty to pass 
this information on to others involved in your care (e.g. your key-worked or psychiatrist). 
Sarah will always try to discuss this with you beforehand and explain why she is concerned.  
 
Representatives of the study Sponsor, NHS Greater Glasgow and Clyde, may look at your 
identifiable personal information to ensure that the study is being conducted correctly. 
They are bound by the same confidentiality rules as Sarah, the research team and your 
care team. 
 
What happens to the consent form?  
To ensure that you information is kept confidential and anonymous, the consent form will 
be kept separately from the transcribed interview and research forms, in a locked filing 
cabinet. This will be within the University of Glasgow premises in the department of 
Mental Health and Wellbeing.  
 
What are the benefits of taking part?  
In general, research improves our knowledge of what people’s difficulties are and what we 
can do to help people overcome these and improve people’s lives. Your participation will 
help increase our knowledge and potentially improve treatment for others in the future. 
With your consent, we will share a summary of your assessment with your key worker or 
psychiatrist and this might contribute to your treatment plan by providing information 
about your memory and thinking. 
 
Is there a downside to taking part?  
It is possible, but unlikely that the interview may prompt you to recall events that you 
might find upsetting. However, you will not be forced to discuss anything you do not want 
to and we do not expect you to become distressed by your participation in the study. 
Many previous studies have been done in this area and it is very rare for people to 
experience negative outcomes, having participated in these studies. If you do feel 
distressed, or have any concerns, you can contact Sarah, Hamish or your mental health 
team in order to access suitable support.  
 
Participation will also use around 2 hours of your time, however the study has been 
designed to use the least amount of time possible.  
 
What happens if I decide not to take part?  
Nothing will happen if you choose not to participate. It will not affect any treatment that 
you receive.  
 
Can I change my mind?  
If you decide to take part, you are able to change your mind and withdraw from the study 
at any time, and you do not need to give a reason. This will not affect any aspect of your 
usual care.  
 
What will happen to the results of the study?  
The results of the study will be reported in Sarah’s Doctoral Thesis which as part of her 
Doctorate in Clinical Psychology degree. It is hoped that the overall results will be 
published in a medical journal and through other routes to raise awareness of the findings. 
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You will not be identified in any report or publication. You are welcome to receive a copy 
of the findings once the project is complete. Please tell Sarah if you would like this and 
provide an address to which a summary of the results can be sent to.  
 
Who is organising and funding the research?  
The University of Glasgow with support from NHS Greater Glasgow and Clyde.  
 
Who has reviewed the study?  
The study has been reviewed by the University of Glasgow and the West of Scotland 
Research Ethics Committee to ensure that it is safe and meets required standards.  
 
Can I speak to someone who is independent of the study?  
Yes. You can speak to Professor Thomas McMillan at the University of Glasgow (Tel: +44 
(0)141 211 0354 or thomas.mcmillan@glasgow.ac.uk ).  
 
What if there is a problem?  
If you have a concern with any aspect of the study, please speak to Sarah who will do her 
best to assist you.  
 
Researchers Contact Details 
Dr  Hamish McLeod 
Doctorate in Clinical Psychology 
Programme Director, 
Institute of Health & Wellbeing,  
University of Glasgow 
Administration Building, 1st Floor 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
Email: Hamish.McLeod@glasgow.ac.uk 
Tel: 0141 211 3922 
Sarah Breustedt,  
Trainee Clinical Psychologist 
Institute of Mental Health & Wellbeing, 
University of Glasgow 
Administration Building, 
1st Floor 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
Email: s.breustedt.1@research.gla.ac.uk 
Tel: 0141 211 0607 
 
 
If you remain unhappy with the conduct of the study and wish to complain formally, you 
can do this through NHS Greater Glasgow and Clyde NHS Complaints by telephoning 0141 
201 4500. 
 
If you feel distressed following your participation in this study, you speak to your key 
worker: ..................................................................................................................................  
 
 
Thank you for taking the time to read this 
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Appendix 2.6: Participant Information Sheet (Clinicians) 
 
 
 
 
 
 
 
 
Invitation to Participate in a Research Project (Clinicians) 
 
Autobiographical memory functioning and response to inpatient treatment for people 
diagnosed with Schizophrenia Spectrum Disorders 
 
 
We would like to invite you to take part in a research study. Before you decide, you need 
to understand why the research is being done and what it would involve for you. Please 
take time to read the following information carefully. Talk to others about the study if you 
wish. Ask us if there is anything that is not clear or if you would like more information. Take 
time to decide whether or not you wish to take part.  
 
Who is conducting the research?  
The research is being carried out by Ms Sarah Breustedt who is a Clinical Psychologist in 
training from the University of Glasgow. Sarah is employed by NHS Greater Glasgow and 
Clyde. The research is being supervised by Dr Hamish McLeod from the University of 
Glasgow. Dr Laura Raymond, Dr Allison Blackett and Dr Ian Mark Kevan, who are all 
Consultant Clinical Psychologists, are supporting the research in inpatient psychiatric 
wards in NHS Greater Glasgow and Clyde. 
 
What is the research about?  
This study is designed to investigate autobiographical memory, which is how people 
remember events that have happened to them in their lives. In particular, we are looking 
at this with people who have been diagnosed with psychosis and have been admitted to 
inpatient mental health services. This kind of research will contribute to understanding of 
the needs of people with psychosis, and to developing new ways to help people recover. 
The study is being undertaken as part of the fulfilment of an academic qualification 
(Doctorate in Clinical Psychology).  
 
Who is being asked to take part?  
We are asking people who are currently inpatients in mental health services who also have 
a diagnosis of schizophrenia and other similar disorders, to take part in the study. We are 
also asking members of staff involved in participants care to take part in recruiting people 
to the study and in assessing their response to treatment. 
 
Why have I been asked to take part?  
You are a member of staff working in a ward where potential participants are being asked 
to take part in the study. 
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What do you mean by the term “autobiographical memory”?  
“Autobiographical memory” refers to a person’s memory of events that have happened in 
their own lives. These can be memories of specific events or of more general periods in a 
person’s life, such as childhood and growing up.  
 
What are you asking me to consent to?  
If you consent to participate, you will be asked by Sarah to let her know if someone who 
might be able to take part in the study is admitted to the ward and Sarah may ask you to 
approach that person and tell them that there is a research study going on which they can 
take part in. If the person seems interested or willing to find out more about the research, 
Sarah will arrange a time to meet the person on the ward and you might be asked to 
introduce Sarah to the person.  
 
You may be asked to make an assessment of participants’ recovery using a brief, validated 
scale. This scale was developed to provide a rating of response to treatment for people 
affected by psychosis. You will be asked to complete this brief assessment at two time 
points, near admission and near discharge. This should take no more than 15 minutes of 
your time in total. 
 
Will the information gathered be confidential?  
All the information provided by staff and patients will be treated as confidential. This 
means that all the information will only be identified by a code and all identifying details 
will be extracted at the earliest possible point in data collection. We will keep all the 
information safe and anonymous. 
  
If participants share information that makes Sarah concerned about their safety or the 
safety of other people, she will have a duty to discuss this with the wider clinical team.  
 
Representatives of the study Sponsor, NHS Greater Glasgow and Clyde, may look at 
identifiable personal information to ensure that the study is being conducted correctly. 
They are bound by the same confidentiality rules as NHS clinical staff. 
 
What happens to the consent form?  
To ensure that you information is kept confidential and anonymous, the consent form will 
be kept separately from the transcribed interview and research forms, in a locked filing 
cabinet. This will be within the University of Glasgow premises in the department of 
Mental Health and Wellbeing.  
 
What are the benefits of taking part?  
In general, research improves our knowledge of what people’s difficulties are and what we 
can do to help people overcome these and improve people’s lives. Your participation will 
help increase our knowledge and potentially improve treatment for people affected by 
psychosis.  
 
With participants’ consent, Sarah will share a summary of the assessment with the key 
worker or psychiatrist and this might contribute to treatment planning by providing 
information about cognitive functioning. 
 
 80 
Is there a downside to taking part?  
Participation will take up approximately 30 minutes of staff time. However the study has 
been designed to use the least amount of time possible.  
 
What happens if I decide not to take part?  
Nothing will happen if you choose not to participate.  
 
Can I change my mind?  
If you decide to take part, you are able to change your mind and withdraw from the study 
at any time, and you do not need to give a reason.  
 
What will happen to the results of the study?  
The results of the study will be reported in Sarah’s Doctoral Thesis which is part of her 
Doctorate in Clinical Psychology degree. It is hoped that the overall results will be 
published in a medical journal and through other routes to raise awareness of the findings. 
You will not be identified in any report or publication. You are welcome to receive a copy 
of the findings once the project is complete. Please tell Sarah if you would like this and 
provide an address to which a summary of the results can be sent to.  
 
Who is organising and funding the research?  
The University of Glasgow with support from NHS Greater Glasgow and Clyde. 
 
Who has reviewed the study?  
The study has been reviewed by the University of Glasgow and the West of Scotland 
Research Ethics Committee to ensure that it is safe and meets required standards.  
 
Can I speak to someone who is independent of the study?  
Yes. You can speak to Professor Thomas McMillan at the University of Glasgow (Tel: +44 
(0)141 211 0354 or thomas.mcmillan@glasgow.ac.uk ).  
 
What if there is a problem?  
If you have a concern with any aspect of the study, please speak to Sarah who will do her 
best to assist you.  
 
Researcher Contact Details 
Dr  Hamish McLeod 
Doctorate in Clinical Psychology Programme 
Director, 
Institute of Health & Wellbeing,  
University of Glasgow 
Administration Building, 1st Floor 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
Email: Hamish.McLeod@glasgow.ac.uk 
Tel: 0141 211 3922 
Sarah Breustedt,  
Trainee Clinical Psychologist 
Institute of Mental Health & Wellbeing, 
University of Glasgow 
Administration Building, 
1st Floor 
Gartnavel Royal Hospital 
1055 Great Western Road 
Glasgow G12 0XH 
Email: s.breustedt.1@research.gla.ac.uk 
Tel: 0141 211 0607 
 
 
If you remain unhappy with the conduct of the study and wish to complain formally, you 
can do this through NHS Greater Glasgow and Clyde NHS Complaints by telephoning 0141 
201 4500. 
Thank you for taking the time to read this 
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Appendix 2.8: Major Research Project Proposal 
Title 
Autobiographical memory functioning and response to inpatient treatment for 
Schizophrenia Spectrum Disorders 
 
Supervisor:  Dr Hamish McLeod 
Date of Submission:  08/02/2016 
Word Count:  2782 
 
Introduction 
There is an established body of evidence that identifies associations between psychotic 
disorders and various cognitive impairments, including over-general autobiographical 
memory and poor mentalizing (Watson et. al., 2012).  There is fairly robust evidence that 
autobiographical memory (AM) is impaired in people diagnosed with schizophrenia or 
psychosis (Berna, et. al, 2015).  However, the mechanisms underpinning impaired AM 
functioning in schizophrenia are not well understood (Wood, et. al., 2006).  This 
relationship is likely to be clinically relevant; it is thought that these deficits may impact 
upon delivery of psychological therapy because the ability to recall specific life events and 
construct coherent narratives of experience is an important component of many 
therapeutic interventions.    
 
Research has demonstrated biases in both latency and specificity of AM retrieval that are 
consistently associated with various psychopathologies. AM functioning commonly shows 
over-general recall, the tendency to give a general description of events despite 
instructions to describe specific life events.  Over-general AM recall has been observed in 
people diagnosed with schizophrenia when compared to matched control participants 
without any current psychiatric diagnoses (Ricarte, et. al., 2014).  One explanation for 
over-general memory (Williams, et. al., 2007; the CaR-FA-X model) suggests three key 
components: 1. capture and rumination, 2. functional avoidance and 3. Impaired executive 
control.  The interaction between variables that may underpin AM impairment in 
schizophrenia requires further examination.   
 
Over-general AM recollections that lack detail feel less proximal to the experience and can 
undermine a subjective sense of self (Tulving, 2002).  Such recall may also lead to a 
reduced perception of agency and these memories are less easily distinguished from 
imagined events or dreams (Klein, 2001).  This has implications for both the experience of 
schizophrenia and the impact these deficits may have on ability to participate in therapies 
that rely on the patient being able to think about their past experiences in some detail.  
Potheegadoo and colleagues (2014) present evidence that specific cueing can improve AM 
recall specificity in people diagnosed with schizophrenia, suggesting that remediation 
strategies may be possible in treating this cognitive deficit.   
 
Further to this, there is evidence that poor mentalization in schizophrenia spectrum 
disorders varies with other aspects of functioning such as AM, symptom burden and 
neurocognitive status.  The terms mentalizing, Theory of Mind and metacognition all refer 
to a persons ability to “think about thinking”, about both their own thoughts and those of 
others (Lysaker, DiMaggio, Buck, Carcione & Nicolo, 2007).  Lysaker and colleagues (2007) 
identified an association with metacognitive deficits and neurocognitive deficit profiles.  
There has been some exploration of this with specific reference to AM functioning in 
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psychosis, multiple deficits in which are relatively established findings within the literature 
(DiMaggio & Semerari, 2001 & DiMaggio, Salvatore, Popolo & Lysaker, 2012). More 
focused and effective treatments must be developed to help people recover and this will 
be aided by improving understanding of the cognitive underpinnings of schizophrenia. 
 
Aims 
This study will examine how changes in AM functioning relate to response to inpatient 
admission for people with schizophrenia spectrum disorders. 
 
The primary research question concerns whether better recovery of AM functioning is 
associated with better quality of self and clinician rated recovery.  
 
Hypotheses 
Based upon findings from the extant literature and from reported clinical observations, it is 
hypothesised that there will be a correlation between AM functioning and response to 
treatment. 
 
We predict that improvements in AM recall specificity will be associated directly with 
clinician and self-rated recovery.  This would be consistent with improved access to AM 
information leading to a more coherent self-narratives and ability to make sense of the 
experience.  We also predict that patients with more mentalization ability, a proxy of 
metacognitive functioning, will demonstrate better recovery. 
 
Recruitment Procedures 
Treating clinicians will identify acute ward inpatients that meet the study inclusion criteria 
and will provide them with verbal and written information about the study.  If the person 
agrees to take part, the Trainee Clinical Psychologist will arrange to meet with them at the 
ward and go through informed consent procedures.  If the person gives consent a further 
appointment date and time will be agreed at which testing will be conducted.  It is 
estimated that the administration of the tests will take approximately 60 minutes in the 
first session and up to 40 minutes in the second.  The tests will examine AM functioning 
(AMT), mentalizing (MAS-A), neuropsychological functioning (HSCT & BMIPB), symptom 
burden (PANSS) and the person’s view of their recovery (QPR).  At both testing sessions, 
the person’s key worker will be asked to complete the Brenner Scale to provide a measure 
of their assessment of the person’s recovery in terms of symptom remission.  Testing will 
be conducted on NHSGGC psychiatric inpatient wards at Gartnavel Hospital and 
Leverndale Hospital.  
 
Inclusion Criteria 
Participants recruited to the study must meet ICD diagnostic criteria for Schizophrenia 
Spectrum Disorder. Individuals recruited to take part in the study must also be able to 
communicate fluently in English. 
 
Exclusion Criteria 
Participants must not have a diagnosis of a learning disability, dementia or another 
neurological condition that could confound the results.  Neither can their symptoms or 
treatment disable them to such a degree that they cannot be considered to have capacity 
to provide informed consent to participate in the research procedures.  However, capacity 
to make an informed decision about taking part in research will fluctuate over time so 
individuals will be given more than one opportunity to take part. 
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Measures 
The Autobiographical Memory Test (AMT: Williams & Broadbent, 1986) will be used to 
examine AM function.  This test is based on Galton’s cue word paradigm which uses lists of 
cue-words to stimulate memory recall (Galton, 1879). It has been widely used in the 
literature and has been found to be a reliable measure of AMT specificity in clinical 
populations (Griffith, Klein, Sumner & Ehlers, 2012).   
 
The Brenner Scale of Clinical Change in Schizophrenia (Brenner Scale: Brenner et.al. 1990) 
will be used to measure the clinician’s assessment of symptom remission.  This scale asks 
clinicians to rate the level of symptom remission they observe in the person with psychosis 
from Level 1 – Clinical Remission to Level 7 – Severely Refractory.  Each level on the scale is 
accompanied by a brief definition of its meaning in terms of response to antipsychotic 
medication and degree of supervision required in social, personal and vocational domains 
of functioning. 
 
The Positive and Negative Symptom Scale (PANSS), which is widely used in the literature 
(Tsapakis, Dimopoulou & Tarazi, 2015) is a 30-item examining a range of symptoms 
observed in patients meeting diagnostic criteria for psychotic disorders.  This measure will 
be administered in order to provide an assessment of overall symptom burden that can be 
subdivided into positive and negative symptoms.  
 
The Metacognition Assessment Scale-Adapted (MAS-A: Semerari, et. al., 2003) has been 
adapted for use with individuals experiencing psychosis and has been extensively used in 
the literature (e.g. Lysaker, et. al., 2005).  The MAS-A will be applied to transcripts from the 
Indiana Psychiatry Illness Interview (IPII: see Lysaker et. al., 2002 for paradigm). The IPII is 
designed to elicit a narrative from the individuals about themself and about illness; it 
typically takes around 30 minutes to complete.  This measure is unique “in that it produces 
a self-narrative in which specific metacognitive acts may appear spontaneously with 
minimal scaffolding by the interview’s structure”(Lysaker et. al., 2010) which minimises 
cueing effects and therefore should produce a more accurate assessment of metacognitive 
capacity.  The MAS-A is subdivided into four constructs, the first of which is Self Reflectivity 
which is briefly defined as the comprehension of one’s own mental state, Understanding 
of Others Mind or the comprehension of other’s mental states, Decentration which is the 
ability to understand that others have independent motives and Mastery which is the 
ability to employ one’s own mental states in order to accomplish cognitive tasks or cope 
with psychological distress.  Metacognition is thought to exist on a continuum of function 
therefore the MAS-A is scored on an ordinal scale with higher scores denoting greater 
complexity.  
 
The Questionnaire on the Process of Recovery Scale (QPR) will be used to assess patient’s 
perception of individual recovery (Neil, et. al., 2009).  This instrument was developed in 
collaboration with service users in the UK and has been validated for use within a 
population with similar demographic characteristics and those individuals who are likely to 
be recruited to take part in this study.  The QPR is a 22-item measure that is divided in to 
intrapersonal factors and interpersonal factors.  Neil and colleagues (2009) conducted an 
evaluation of the validity of the QPR and reported that it has good internal consistency, 
construct validity and reliability, and as such is suitable for use as a clinical and research 
tool to assess and promote recovery in psychosis. 
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The Hayling Sentence Completion Test (Burgess & Shallice, 1997) is a brief verbal test of 
executive functioning.  The test consists of two sets of 15 sentences all of which have the 
last word missing. The first test yields a measure of response initiation speed and the 
second measures response suppression ability and thinking time.  This test has been used 
in repeated measures designs (Wood, Brewin & McLeod, 2006) however effects of 
learning could not be excluded so conclusions about any observed improvements would 
be somewhat limited. 
The Brain Injury Rehabilitation Trust (BIRT) Memory and Information Processing Battery 
will be used to provide a measure of general memory functioning.  The BMIPB is an 
extension of the Adult Memory and Information Processing Battery and it provides a 
repeatable assessment of memory (recall and recognition) and speed of processing. 
 
Design 
This research study employs a repeated measures design examining AM functioning and 
response to routine inpatient treatment.  Data will be collected from a convenience 
sample of persons diagnosed with Schizophrenia Spectrum Disorder.  Approximately 30 
individuals will be recruited to take part in the study.  All participants will complete the 
same battery of tests at T1 and the AMT will be administered at both testing sessions.  At 
T2 clinicians will complete the Brenner Scale and participants will complete the QPR.  If the 
participant agrees, at T2 neurocognitive tests and PANSS will also be repeated.  Testing at 
T1 will take an estimated minimum time of 80 minutes.  Testing at T2 will take a minimum 
of 20 minutes and up to 60 minutes if the participant consents to repeated symptom 
(PANSS) and neuropsychological testing (BMIPB). 
 
Table 1: Assessment and Estimated Administration Time  
Test Administration time 
AMT 15 
Brenner Scale^ 2 
PANSS 30 
IPII/MAS-A* 20 
QPR^ 5 
HSCT* 5 
BMIPB 10 
Total: 87 
*This measure will be administered at T1 only 
^This measure will be administered at T2 only 
 
T1 testing will be conducted in Gartnavel and Leverndale acute inpatient wards. The 
researcher will attend clinical meetings on the wards or otherwise ensure that she 
facilitates communication between herself and treating clinicians so that when a 
participant is nearing discharge from the ward T2 testing can be administered.  If the 
participant is discharged before T2 testing can be carried out, the researcher will arrange 
an outpatient appointment with the participant and will provide transport by taxi to that 
appointment.  Outpatient facilities are available at the Leverndale ward and use of them 
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has been provisionally agreed but contingencies for Gartnavel ward have yet to be 
identified. 
 
Data Analysis 
The first stage of data analysis will test for a correlation between AMT score and Brenner 
Scale rating over time.  AMT specificity at both time points will be calculated using a 
paired-samples t-test.   
 
Further descriptive analysis will be conducted to explore scores on measures of 
mentalizing, symptom burden, neuropsychological functioning and perception of recovery 
both over time and between the groups. 
 
Justification of Sample Size 
Within the resources available it is estimated that 30 participants can be recruited; if an 
average of five participants are recruited per week, six weeks of recruitment will yield a 
sample of 30 participants.  If a third are lost to follow up then repeated measures analysis 
will be applied to a sample of 20 people and the 10 remaining data sets will be analyzed 
for descriptive purposes.  This would be achievable within 12 to 14 weeks with a testing 
interval of two weeks.  Data collection could be carried out between January and April 
2017. 
Diagram 1: Estimated Recruitment Flow Chart  
 
A previous study (McLeod, unpublished data) using a similar paradigm and sample size 
(repeated measures n=20) reported small to medium effect sizes for the difference in AMT 
specificity score and the target sample size is based upon this precedent.  
 
Health and Safety Issues 
Risks: 
The risks to participants and the Trainee Clinical Psychologist will not be greater than those 
present in routine clinical practice.  The Trainee will follow NHS Health and Safety 
protocols at all times.   
Burdens: 
There will be additional burdens placed on participants in the research due to the 
completion of measures that would not be used as part of routine assessment or 
treatment.  Completing the assessment battery is likely to take approximately 100 minutes 
in total, over two sessions.  However, being involved in contributing to the understanding 
60 + 88 
= 148
• Total no. of beds at 
GRH & Leverndale
n=74
• Estimate that 50% will be 
eligible to participate in 
study
n=27
•Estimate 
that 50% 
will consent
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and treatment of psychosis may be considered a possible benefit for the individual (it may 
feel empowering) and the results of the neuropsychological assessment may be used to 
inform the person’s treatment.  In addition, travel costs for attendance at the second 
testing session will be paid for participants who are discharged before follow up is 
completed.  
 
Ethical Issues 
Should participants experience distress (e.g. recall of trauma), this will be responded to by 
the Trainee Clinical Psychologist in the same manner as when this occurs within a clinical 
session and the person may be offered a break or to stop the assessment. The Trainee 
Clinical Psychologist will also be able to notify ward staff of difficulties and ensure that 
information pertaining to the person’s wellbeing is shared with relevant staff.  NHS 
procedures will be followed if any criminal, or other, disclosure occurs during the study.  
 
Settings & Equipment 
The research will be conducted in NHS psychiatric inpatient settings.  Hard copies of the 
BIRT Memory Impairment and Processing Battery and Hayling Sentence Completion Test 
will be required and these will be borrowed from the University Department or local 
Mental Health Services. 
 
Financial Resources 
Photocopying, printing and a digital voice recorder will be borrowed from the University.  A 
bid for £150 of research funding will be made to the Institute for Health and Wellbeing in 
order to pay for participant transport to outpatient services for follow up testing at T2. 
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